Preclinical drug screening identifies novel stratified treatment options according to the consensus molecular subtypes of colorectal cancer
In two recent publications (Eide PW et al. Sci Rep; Sveen A*, Bruun J* et al. Clin Cancer Res), scientists in the Lothe lab., Department of Molecular Oncology, have identified novel potential treatment strategies for colorectal cancer (CRC), guided by the consensus molecular subtypes (CMS). Combining algorithm development, for translation of CMS classification to preclinical models, with drug screening of classified cell lines and patient-derived xenografts (PDXs) in collaboration with the Finnish Institute for Molecular Medicine and Vall d´Hebron Institute of Oncology, a potential to overcome chemoresistance in the poor prognostic CMS4-mesenchymal group was identified by combination therapy with 5-fluorouracil (5-FU) and HSP90 inhibitors.
Dr Anita Sveen received the Young Investigator prize at Onkologisk Forum for her research accomplishments
Anita Sveen received the YI prize worth 50,000 NOK at Onkologisk Forum, the annual meeting for oncologists, for her research accomplishments on computational oncology.